Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_1
3
50%
Ph phase_2
3
50%

Phase Distribution

3

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
3(50.0%)
Phase 2Efficacy & side effects
3(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(5)
Terminated(1)

Detailed Status

Completed5
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
83.3%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (50.0%)
Phase 23 (50.0%)

Trials by Status

completed583%
terminated117%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_2

Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout

NCT05818085
terminatedphase_2

Extension Study of ABP-671 in Participants With Gout

NCT06276556
completedphase_2

A Study to Assess the Efficacy, Safety, and Pharmacokinetics of ABP-671 in Patients With Gout or Hyperuricemia

NCT04638543
completedphase_1

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 in Healthy Subjects

NCT03906006
completedphase_1

Study to Investigate the Effects of Food on Relative Bioavailability of ABP-671 Tablets in Healthy Subjects

NCT04303039
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT05818085Phase 2

Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout

Completed
NCT06276556Phase 2

Extension Study of ABP-671 in Participants With Gout

Terminated
NCT04638543Phase 2

A Study to Assess the Efficacy, Safety, and Pharmacokinetics of ABP-671 in Patients With Gout or Hyperuricemia

Completed
NCT03906006Phase 1

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 in Healthy Subjects

Completed
NCT04303039Phase 1

Study to Investigate the Effects of Food on Relative Bioavailability of ABP-671 Tablets in Healthy Subjects

Completed
NCT04060173Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6